Opendata, web and dolomites

GLYMPHARMA SIGNED

Modulation of the glymphatic system: a novel tool for drug delivery to the central nervous system

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GLYMPHARMA project word cloud

Explore the words cloud of the GLYMPHARMA project. It provides you a very rough idea of what is the project "GLYMPHARMA" about.

coupled    flow    transfer    brain    function    endogenous    anaesthesia    waste    time    nervous    performed    antibodies    venous    nedergaard    3d    route    opportunity    experts    activates    safety    sleep    lab    nature    astrocytic    cerebrospinal    basis    concentrations    copenhagen    clinicians    essentially    discovered    career    basic    discovery    consists    para    techniques    arterial    mice    convective    prevalence    clearance    neurological    citizens    diseases    influx    knockout    therapies    modulators    mammals    aquaporin    protected    drug    university    exploited    water    structures    excellent    lay    fluxes    microdialysis    aqp4    proposes    drugs    channels    life    mass    spatial    glymphatic    everyday    spectrometric    compounds    resolution    movements    blood    facilitates    glympharma    efficacy    trained    shown    imaging    pharmacokinetics    barrier    difficult    central    deep    world    interstitial    cns    micropet    macroscopic    fluid    free   

Project "GLYMPHARMA" data sheet

The following table provides information about the project.

Coordinator
KOBENHAVNS UNIVERSITET 

Organization address
address: NORREGADE 10
city: KOBENHAVN
postcode: 1165
website: www.ku.dk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Total cost 200˙194 €
 EC max contribution 200˙194 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-10-01   to  2020-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) coordinator 200˙194.00

Map

 Project objective

The prevalence of neurological diseases in the world is greatly increasing. However, drug development for central nervous system (CNS) diseases is difficult due to its protected nature behind the blood-brain barrier. The recently discovered glymphatic pathway consists of a para-arterial cerebrospinal fluid influx path and a para-venous interstitial fluid clearance route, coupled through convective flow of interstitial fluid supported by astrocytic aquaporin 4 (Aqp4) water channels. This macroscopic waste clearance system activates during sleep or anaesthesia. It also facilitates brain-wide distribution of endogenous compounds. Its function may explain the importance of sleep to mammals.

GLYMPHARMA proposes that the glymphatic system essentially affects the concentrations of drugs in the CNS and that it can be exploited to facilitate CNS drug availability. Enhancing glymphatic fluxes have already been shown to increase the availability of CNS-targeted antibodies in deep brain structures.

Studies will be performed at University of Copenhagen, Nedergaard lab, known for the discovery of the glymphatic system. I will use three state-of-the-art techniques to study glymphatic pharmacokinetics in mice: microdialysis to measure free drug concentrations, novel mass spectrometric techniques enabling spatial resolution, and microPET imaging to measure real-time 3D drug movements. Several glymphatic modulators (anaesthesia, sleep, Aqp4 knockout mice) will be used.

GLYMPHARMA will be an excellent opportunity for my career development and it will facilitate real two-way knowledge transfer. I will be trained by the world-leading experts in the field. GLYMPHARMA will interest both basic researchers and clinicians and may impact the everyday life of citizens. The study may lead to the discovery of a novel drug delivery route and it may increase efficacy and safety of current drug therapies. These studies will lay the basis on our understanding of glymphatic pharmacokinetics.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLYMPHARMA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GLYMPHARMA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More  

PNAIC (2018)

Positive and Negative Asymmetry in Intergroup Contact: Its Impact on Linguistic Forms of Communication and Physiological Responses

Read More  

NPsVLCD (2019)

Natural Product-Inspired Therapies for Leishmaniasis and Chagas Disease

Read More